Clinical investigation of medicinal products for the treatment of attention deficit hyperactivity disorder (ADHD) - Scientific guideline
HumanScientific guidelines
This document provides guidance on the evaluation of new medicinal products for the treatment of attention deficit hyperactivity disorder with focus on the childhood onset.
Keywords: Attention deficit hyperactivity disorder (ADHD), children, adults, psychostimulants
Current effective version
Guideline on the clinical investigation of medicinal products for the treatment of attention deficit hyperactivity disorder (ADHD)
AdoptedReference Number: EMEA/CHMP/EWP/431734/2008 Rev. 2 Corrigendum
English (EN) (158.21 KB - PDF)
First published: Last updated:
Document history
Guideline on the clinical investigation of medicinal products for the treatment of attention deficit hyperactivity disorder (ADHD)
AdoptedReference Number: EMEA/CHMP/EWP/431734/2008 Rev. 2 Corrigendum
English (EN) (158.21 KB - PDF)
First published: Last updated:
Overview of comments received on 'Guideline on the clinical investigation of medicinal products for the treatment of attention deficit hyperactivity disorder (ADHD)' (EMEA/CHMP/EWP/431734/2008)
AdoptedReference Number: EMEA/CHMP/EWP/431734/2008
English (EN) (401.47 KB - PDF)
First published: Last updated:
Draft guideline on the clinical investigation of medicinal products for the treatment of attention deficit hyperactivity disorder (ADHD)
Draft: consultation closedReference Number: EMEA/CHMP/EWP/431734/2008
English (EN) (140.18 KB - PDF)
First published: Last updated:
Draft concept paper on development of guideline on the treatment of attentional deficit hyperactivity disorder (ADHD)
Draft: consultation closedReference Number: EMEA/CHMP/EWP/20119/2008
English (EN) (36.41 KB - PDF)
First published: Last updated:
Related content
- Clinical efficacy and safety: nervous system
- Directive 2001/83/EC
- Ethical considerations for clinical trials on medicinal products conducted with the paediatric population
- Adjustment for baseline covariates in clinical trials
- ICH E1 Population exposure: the extent of population exposure to assess clinical safety
- ICH E4 Dose response information to support drug registration
- ICH E9 statistical principles for clinical trials
- ICH E10 Choice of control group in clinical trials
- ICH E11(R1) step 5 guideline on clinical investigation of medicinal products in the pediatric population - Scientific guideline
- ICH M3 (R2) Non-clinical safety studies for the conduct of human clinical trials for pharmaceuticals - Scientific guideline
- Missing data in confirmatory clinical trials
- Need for non-clinical testing in juvenile animals on human pharmaceuticals for paediatric indications - Scientific guideline
- Pharmacokinetic studies in man